A prospective, randomized, controlled, open-label study will be carried out on 80 post-menopausal women affected by the metabolic syndrome (criteria are described in NIH ATP III). After a written informed consent, women will be randomly treated for 6 months with hypocaloric diet (control group) or with diet and a supplementation of myo-inositol 2000 mg plus cocoa polyphenols 30 mg and plus isoflavones 80 mg. will be given randomly Eighty post-menopausal women, affected by metabolic syndrome will be randomized into two groups: 40 treated with myo-inositol 2 g twice per day and forty treated with placebo for six months. The investigators hypothesize that the administration of myo-inositol would improve the insulin-receptor activity in these women, reducing insulin resistance.
Inclusion Criteria: post-menopausal women (12 months after last menstruation) affected by metabolic syndrome according to ATP III, 2001. At least 3 of following 5 criteria must be present: 1. waist circumference \> 88 cm 2. Triglycerides \> 150 mg/dl 3. HDL-cholesterol \< 50 mg/dl 4. Fast glycemia \> 110 mg/dl 5. Systolic blood pressure \> 135 mmHg. diastolic \> 85 mmHg - Exclusion Criteria:1) post-menopausal women with less than 12 months from the last menstruation 2) less than 3 criteria according with ATP III 3) TSH \> 3.5 4) in treatment with drugs lowering glycemia or cholesterol 5) allergy to cocoa
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Enrollment
80
Dietary supplement: myo-inositol 2000 mg plus cocoa polyphenols 30 mg and plus isoflavones 80 mg
University Hospital
Messina, Italy
percentage reduction of women with metabolic syndrome
evaluation of metabolic syndrome criteria according with ATP III 2001
Time frame: at baseline and after 6 months.
reduction of insulin resistance
evaluation of HOMA-IR
Time frame: at baseline and after 6 months
Improvement of lipid profile
reduction of serum triglycerides and increase of HDL-cholesterol
Time frame: at baseline and after 6 months
variation in serum concentration of adiponectin, visfatin and resistin
Time frame: at baseline and after 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.